Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences Inc (NASDAQ: PCRX) is a leader in non-opioid pain management, offering innovative therapies that reduce reliance on traditional opioids. This page provides investors and healthcare professionals with timely updates on the company’s latest developments, including regulatory milestones, clinical advancements, and strategic initiatives.
Access PCRX’s official press releases, earnings reports, and analysis of key events shaping its position in the specialty pharmaceutical sector. Track updates on flagship products like EXPAREL® (long-acting local anesthetic) and iovera® (targeted cold therapy), along with emerging pipeline candidates such as PCRX-201 for osteoarthritis.
Discover how Pacira’s proprietary drug delivery platforms and commitment to evidence-based solutions address critical needs in postsurgical recovery and chronic pain management. Stay informed about partnerships, regulatory approvals, and market expansion efforts driving the company’s growth.
Bookmark this page for direct access to PCRX’s verified news, ensuring you never miss developments impacting its role in transforming pain treatment. Visit regularly to monitor progress in non-opioid innovation and regenerative health solutions.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its Q2 financial results on August 3, 2022, before U.S. market opens. Following the report, a conference call is scheduled at 8:30 a.m. ET. The call can be accessed by dialing 1-800-715-9871 (US) or 1-646-307-1963 (international), using passcode 9287305. Interested investors can join via webcast on Pacira's investor page. The company focuses on non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at reducing opioid reliance in pain management.
Pacira BioSciences reported preliminary revenues of $169.4 million for Q2 2022, up from $135.6 million in Q2 2021. Sales were driven by EXPAREL and ZILRETTA, with average daily sales of EXPAREL at 105% of the prior year for Q2. The company is focused on expanding its portfolio of non-opioid pain management solutions. Despite pandemic disruptions, they are optimistic about growth, especially in outpatient settings. The company remains cautious about future guidance due to ongoing challenges, including labor shortages and potential COVID-19 impacts.
Pacira BioSciences and the National Safety Council announced their partnership to launch the Connect2Prevent program, aimed at educating employees and their families on preventing opioid misuse and addiction. The program features a 10-12 week curriculum addressing the risks of opioids, stigma, and alternatives to pain management. This initiative, which starts piloting this summer, encourages meaningful discussions about substance use. Key data highlights the serious risks, such as a 33% higher chance of misuse for those using opioids before high school.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for May 2022, with EXPAREL achieving $44.9 million, a 9% increase from $41.2 million in May 2021. Average daily sales for EXPAREL reached 104% of the prior year, reflecting an increase in utilization. Iovera° sales rose slightly to $1.1 million. CEO Dave Stack highlighted EXPAREL's growth amid ongoing pandemic challenges and noted robust performance of ZILRETTA with over 220 new accounts. The company currently refrains from providing 2022 revenue guidance due to uncertainties from COVID-19 and elective surgery recovery.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:00 AM ET in New York. The live audio of the event can be accessed via the company's website, and a replay will be available for two weeks thereafter.
Pacira is dedicated to providing non-opioid treatment options, including three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº. The company aims to redefine opioid usage and address chronic pain and other debilitating conditions.
Pacira BioSciences partnered with the National Senior Games Association to achieve a GUINNESS WORLD RECORDS title for the Largest Game of Freeze Dance, held on May 16, 2022, with 1,308 participants in Fort Lauderdale, Florida. This event highlighted the company's non-opioid pain relief device, iovera°, which provides up to 90 days of osteoarthritis pain relief. Amber Sears from Pacira emphasized the initiative's role in promoting non-opioid options for chronic pain management, aiming to educate patients about viable alternatives to opioid treatments.
Pacira BioSciences reported preliminary net product sales for April 2022, with EXPAREL achieving $44.8 million, marking a 109% increase in average daily sales compared to April 2021. Sales of iovera° were $1.1 million, down from $1.5 million in the previous year. The company remains financially strong with an adjusted EBITDA of $53.8 million for Q1 2022. Despite ongoing pandemic-related challenges impacting elective surgeries, Pacira's leadership anticipates robust revenue growth. The company has not provided 2022 financial guidance due to uncertainties surrounding COVID-19.
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) will participate in two upcoming healthcare conferences:
- RBC Capital Markets Global Healthcare Conference on May 17 at 8:00 AM ET.
- H.C. Wainwright Global Virtual Investment Conference on May 24 at 7:00 AM ET.
Live audio can be accessed on the company’s website, with replays available for two weeks post-events. Pacira's commitment lies in providing non-opioid pain management solutions.
Pacira BioSciences (Nasdaq: PCRX) reported a strong first quarter of 2022, with total revenues reaching $158 million, marking a 33% increase year-over-year. Net income was $6.8 million or $0.15 per share, while adjusted EBITDA stood at $53.8 million. Significant sales growth for EXPAREL at $129.2 million reflects operational resilience amid COVID-related challenges. The successful integration of the Flexion acquisition contributed to ZILRETTA's sales of $23.6 million. Looking forward, Pacira is optimistic about upcoming clinical studies and new product registrations.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its first quarter financial results on May 4, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. ET, with participation options available for both domestic and international callers. The call will also be accessible via webcast on the company’s investor page. Pacira aims to provide non-opioid pain management solutions and has three commercial treatments: EXPAREL, ZILRETTA, and iovera, focusing on reducing opioid reliance.